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 INTRODUCTION
 Gluten-related disorders (GRDs) represent a spectrum of diverse 
clinical manifestations sharing a common trigger, the ingestion 
of gluten ( 1 ). h e most widely recognized and best-characterized 
disease within this spectrum is coeliac disease (CD), also known 
as gluten-sensitive enteropathy.
 Classic presentations of CD such as abdominal bloating, weight 
loss, diarrhea, anemia, and malabsorption are no longer the norm 
and patients can present with minimal or no gastrointestinal 
AQ5
symptoms and diverse extraintestinal manifestations af ect-
ing other organs such as the skin and the nervous system ( 2,3 ). 
Although the presence of enteropathy, dei ned by the triad of 
villous atrophy, crypt hyperplasia, and increased intraepithelial 
lymphocytes, remains the cornerstone of the diagnosis of CD, the 
diagnosis of the whole spectrum of GRDs is problematic. h is 
is particularly the case for the relatively new entity belonging to 
the spectrum of GRDs, non-coeliac gluten sensitivity (NCGS). 
NCGS is currently dei ned by clinical evidence of improvement 
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of symptoms following the introduction of gluten-free diet (GFD) 
in the absence of enteropathy ( 4,5 ). Both innate and adaptive 
immune responses to wheat proteins have been demonstrated in 
the gut of such patients. h e concept of sensitivity to gluten in 
the absence of enteropathy is not new. Patients with extraintes-
tinal manifestations because of sensitivity to gluten (e.g., gluten 
ataxia and dermatitis herpetiformis (DH) may not have enter-
opathy, but yet respond to a GFD ( 6 ) h e reasons behind such 
dif erences in the gut response remain unknown. Currently, it 
also remains unclear which serological markers alone or in com-
bination should be used in diagnosing the whole spectrum of 
GRDs, and in particular NCGS ( 7 ). Although some markers such 
as anti-tissue transglutaminase (TG2) autoantibodies detected 
as anti-endomysium antibodies by ELISA (anti-TG2 antibodies) 
are sensitive and specii c in diagnosing CD, such antibodies 
will usually be absent in patients with NCGS. h is may rel ect 
the absence of detectable levels of circulating antibodies in some 
cases where the immune response is distant from the gut (e.g., 
cerebellum in gluten ataxia). Anti-gliadin antibodies (AGAs) 
may be an indicator of NCGS as up to 50% of such patients pre-
senting to gastroenterologists have detectable circulating levels, 
primarily of IgG AGAs ( 8 ). More specii c markers, i.e., antibodies 
directed at autoantigens likely to be responsible for extraintesti-
nal manifestations, have been identii ed but are not yet in general 
use. Antibodies against TG3, an epidermal TG, have been found 
in patients with DH, whereas antibodies against TG6, a brain 
expressed TG, have been found in patients with gluten ataxia 
( 9,10 ). However, the extent of overlap between NCGS, DH, and 
gluten ataxia is unclear at present and awaits the development of 
validated diagnostic approaches.
 h e use of the HLA type as an aid in the diagnosis has also been 
advocated given that over 95% of patients with CD have the HLA-
DQ2, and the remainder having HLA-DQ8. HLA type, however, 
cannot be interpreted in isolation as DQ2 is found in up to 25% of 
the healthy population, of which only a fraction will ever develop 
GRDs. Furthermore, while there is over-representation of DQ2 in 
patients with NCGS, a signii cant minority do not have the HLA-
DQ2 or -DQ8 and yet appear to respond to a GFD. It is plausible 
that patients who have serological evidence of sensitivity to gluten 
without enteropathy, who also have the HLA-DQ2 or -DQ8, and 
appear to respond to GFD may be susceptible to develop entero-
pathy with ongoing exposure to gluten ( 11 ).
 Our research into the neurological manifestations of GRD started 
20 years ago. h e presence or absence of enteropathy did not inl u-
ence our diagnosis as these patients had no clinical features, either 
gastrointestinal or neurological, to distinguish between those with 
and those without enteropathy and had no explanation other than 
gluten sensitivity for their neurological problem.
 Here we present the spectrum of neurological manifestations 
seen in the context of NCGS and we compare this with neuro-
logical manifestations seen in the context of CD (with neurological 
presentation). h e aim was to tease out any potential dif erences 
between these two groups that may imply dif erent pathophysio-
logical mechanisms being responsible depending on the presence 
or not of enteropathy.
AQ6
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 METHODS
 We undertook a retrospective analysis of all consecutive patients 
presenting with neurological dysfunction related to gluten sensi-
tivity, to a neurology clinic (Neuroscience Department, Royal Hal-
lamshire Hospital, Shei  eld, UK), with an interest in neurological 
manifestations of GRD for 20 years between 1994 and 2014. No 
alternative etiology for their neurological dysfunction was found 
despite extensive investigations. All patients had been clinically 
assessed on several occasions and almost all remained under 
active follow-up on a six-monthly or yearly basis. All patients 
included had detectable circulating AGAs (IgG and or IgA) at 
baseline as this was the only serum marker for gluten sensitivity 
available in 1994. Additional immunological markers (anti-
endomysium antibodies and TG2 IgA antibodies) were assessed 
at er they became locally available. All the serological testing was 
carried out at the regional clinical immunology lab. TG6 antibody 
testing was undertaken as previously described in some but not 
all patients as this test became available in 2008 ( 12 ) TG6 test-
ing is not as yet readily available and such testing was undertaken 
in the investigators lab. All patients underwent duodenal biopsy, 
HLA typing, and were of ered GFD (irrespective of the presence 
or absence of enteropathy). All patients were reassessed clinically 
and with repeat brain imaging including magnetic resonance 
spectroscopy of the cerebellum (for patients with gluten ataxia) 
and magnetic resonance imaging of the brain in gluten encepha-
lopathy or neurophysiology for patients with gluten neuropathy. 
All patients included had evidence of clinical and/or imaging 
and/or neurophysiological improvement on repeat assessments. 
Details of the methodology for such assessments (neurophysio-
logy, magnetic resonance spectroscopy, and clinical assessment of 
the ataxia) has been described in detail elsewhere ( 6,13,14 ). h e 
above investigations and follow-up represent our normal clinical 
practice in caring for such patients.
 h e patients were separated into two groups based on the pres-
ence or absence of enteropathy. Group 1 consisted of all patients 
with enteropathy (triad of villous atrophy, crypt hyperplasia, and 
increased intraepithelial lymphocytes) on biopsy (CD). Group 2 
consisted of patients without enteropathy (NCGS). Group 2 was 
further subdivided into those patients with the HLA-DQ2 or 
-DQ8 (Group 2a) and those patients with HLA other than DQ2 
or DQ8 (Group 2b). We also compared those patients in Group 
2 with circulating TG2 antibodies with those without circulating 
TG2 antibodies.
 Planned comparisons included the age of onset of symptoms, 
the prevalence of HLA subtypes and antibodies in the compara-
tor groups. h e frequency of dichotomous variables was compared 
using the  χ 2 test. Means of interval data were compared using 
Student’s  t -test, Fisher’s exact test, or analysis of variance where para-
metric or Kruskal–Wallis analysis of variance if non-parametric.
 RESULTS
 Comparison of CD (Group 1) vs. NCGS (Group 2)
 Between 1994 and 2014, a total of 700 patients have been 
seen and assessed in a neurology clinic specializing in gluten 
© 2016 by the American College of Gastroenterology The American Journal of GASTROENTEROLOGY
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sensitivity. Out of these, 562 patients were included in this report. 
h e remaining patients were excluded for the following reasons: 
refused intestinal biopsy, HLA type not available, non-compliant 
with GFD with persistently positive serology, neurological mani-
festation developed, and patient referred at er the diagnosis of CD 
was made (total of 139 patients). Of the 562 patients included in 
this report, 228 (41%) had evidence of enteropathy on duodenal 
biopsy (Group 1). Group 2 consisted of 334 patients (59%) with 
normal biopsies (NCGS). h e mean age at the onset of neurologi-
cal symptoms in Group 1 was 53 years (range 13–90) and in Group 
2 it was 57 years (range 14–87). Patients in Group 1 developed 
neurological symptoms signii cantly earlier than Group 2 ( P <0.01 
by Kruskal–Wallis one-way analysis of variance). h e mean age 
at diagnosis of CD of patients in Group 1 was 52.6±15.3 years. 
h is was compared with a mean of 43.8±15 years for patients 
diagnosed with CD presenting to the gastrointestinal department 
( P <0.0001 by Student’s  t -test). h e mean duration of the neuro-
logical symptoms before the diagnosis of gluten-related disease 
was not signii cantly dif erent among the two groups ( P =0.06 by 
analysis of variance).
 HLA type
 As in the case of patients with classical CD with gastrointestinal 
presentation, the HLA-DQ2 (DQA1*05:01–DQB1*02:01) was 
present in 214/228 (94%) of all patients in Group 1 and DQ8 
(DQA1 03:01–DQB1 03:02) in 8/228 (4%). h ere were four 
patients with biopsy-proven enteropathy who had only one of the 
DQB1*02 alleles.
 In Group 2, 148/333 (44%) of patients had the HLA-DQ2 and 
60 (18%) had the HLA-DQ8. h e prevalence of the HLA-DQ2 
or -DQ8 in Group 2 was therefore 62%. h e remaining patients 
had neither HLA-DQ2 nor -DQ8. All but six of these patients had 
the HLA-DQB1*06 or -DQB1*05 (both come under the umbrella 
of DQ1).
 Type of neurological manifestation per group
 In Group 1 (228 patients), the most common neurological mani-
festations were cerebellar ataxia 41%, followed by peripheral 
neuropathy 30% (of which 80% had sensorimotor axonal length-
dependent symmetrical neuropathy and 20% had sensory ganglio-
nopathy) and encephalopathy 21%. Less common manifestations 
included ataxia with myoclonus 11, myopathy 9, myelopathy 6, 
stif  person syndrome 3, neuromyotonia 1, and chorea 1 (some 
patients had more than one manifestation).
 In Group 2 (334 patients), the most common neurological 
manifestations were peripheral neuropathy 54% (of which 69% 
had sensorimotor axonal length-dependent symmetrical neuro-
pathy and 31% had sensory ganglionopathy), followed by cere-
bellar ataxia 46% and encephalopathy in 10%. Less common 
manifestations included myopathy 8, myelopathy 6, stif  person 
syndrome 5, chorea 3 and myoclonic ataxia 2, and epilepsy with 
occipital calcii cations 1 (some patients had more than 1 mani-
festation).
 Overall, the prevalence of ataxia was similar in the two groups, 
but there was an over-representation of encephalopathy in 
AQ9
AQ10
Group 1 and of neuropathy and ganglionopathy in Group 2 
( P =0.002 by  χ 2 test).  Figure 1 summarizes the frequency of the 
neurological manifestations within the two groups.
 Anti-gliadin antibodies
 In Group 1, the total number of patients with circulating IgG 
AGAs was 78%, IgA AGAs was 65%, and with 43% having both 
circulating IgG and IgA ( Table 1 ). In Group 2, 68% had circu-
lating IgG AGAs, 53% for IgA and 21% for both. We compared 
these i gures with 100 patients with newly diagnosed CD who 
presented to gastroenterology clinics (classic CD). In this group, 
88% had IgG AGAs, 75% IgA, and 63% had both. While by dei ni-
tion Groups 1 and 2 had to have circulating AGAs to be included 
(i.e., 100% positivity), in the case of the 100 patients with newly 
diagnosed CD presenting to gastroenterologists, the total percent-
age with AGA positivity was 82%.  Table 1 summarizes the above 
i ndings.
AQ11
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Ataxia
Group 1
Group 2
Sensorimotor neuropathy
Ganglionopathy
Encephalopathy
Myoclonic ataxia
Myopathy
Myelopathy
SPS
Chorea
Neuromyotonia
Ataxia
Sensorimotor neuropathy
Ganglionopathy
Encephalopathy
Myoclonic ataxia
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Myelopathy
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Chorea
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1%
1%
1%
8%
18%
31%
38%
1%
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4%
20%
2%
39%
6%
23%
 Figure 1 .  Distribution of the different types of neurological manifestations 
in the two groups. There is a greater proportion of patients with encepha-
lopathy in Group 1 and a greater proportion of neuropathy and gangliono-
pathy in the patients in Group 2 ( P =0.002 by  χ 2 test).
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 Anti-TG2 autoantibodies
 Baseline TG2 IgA antibodies were available in some but not all the 
patients included, as the availability of the assay for these antibod-
ies was limited at the start of this study. In Group 1, 105/115 (91%) 
of patients had circulating antibodies against TG2 as compared 
with 67/229 (29%) in Group 2. h e proportion of patients positive 
for TG2 IgA antibodies who also had biopsy-proven CD present-
ing to the gastroenterology department was 97% (based on 100 
consecutive patients). h is illustrates, as expected, that there is a 
high degree of correlation between enteropathy and circulating 
anti-TG2 antibodies.  Table 1 summarizes the above i ndings.
 Anti-TG6 autoantibodies
 h e availability of TG6 antibody analysis/testing was limited as 
TG6 autoantibodies were not discovered until 2006, and their 
importance in neurological manifestations of GRD was not estab-
lished until 2008. Testing for TG6 was therefore carried out in a 
smaller group of patients from each group and baseline samples 
were not available in all cases. Patients without baseline analysis 
and subsequently testing negative were excluded given that they 
were on GFD and hence no clear conclusion could be drawn. In 
Group 1, 36/54 (67%) of patients had circulating TG6 (IgG and 
or IgA) antibodies. In Group 2, 68/114 (60%) of patients had cir-
culating TG6 antibodies. h e prevalence of TG6 antibodies in 
patients with newly diagnosed CD presenting to gastroenterolo-
gists was 38/100 (38%). h ere was a signii cant dif erence in the 
prevalence of TG6 between the neurology groups and the patients 
with CD presenting to gastroenterologists ( P <0.01  χ 2 test).  Table 1 
summarizes the above i ndings.
 Severity of neurological manifestations per group
 For the purpose of comparing the severity of the neurological 
manifestations between each group, we concentrated on the two 
most common types of manifestations, gluten ataxia and gluten 
neuropathy. h e severity of ataxia was assessed at presentation, 
using a simple clinical rating scale: mild (patient able to walk 
unaided), moderate (patient needs walking aids/support to be 
able to walk), and severe (patient is wheelchair bound) ( 15 ). In 
Group 1, 69% of patients had mild ataxia, 17% moderate, and 14% 
severe. In Group 2, 77% had mild, 15% moderate, and 8% severe. 
h ere were no signii cant dif erences between the two groups.
 h e severity of neuropathy was assessed using neurophysio-
logical parameters (neurophysiological abnormalities coni ned to 
lower limbs, mild, involvement of arms but sparing radial nerve, 
moderate, involvement of radial nerve as well, severe). In Group 1, 
27% had mild, 40% moderate, and 33% severe neuropathy. In 
Group 2, 42% had mild, 22% moderate, and 36% severe neuro pathy. 
Mild neuropathy was more common in Group 2 with moderate 
and severe neuropathy being more common in Group 1 ( P <0.01 by 
 χ 2 test). h e above observations are summarized in  Figure 2 .
 Group 2 (NCGS) comparison between patients with positive and 
negative TG2 autoantibodies and those with HLA-DQ2/DQ8 vs. 
those without
 We also performed a comparison between those patients in 
Group 2 with (67) and those without (162) TG2 antibodies. h e 
rationale for this was to establish if the presence or absence of 
such antibodies had any bearing on such neurological manifesta-
tions. We found no signii cant dif erences in the age at onset of 
neurological manifestations between those with and those with-
out TG2 antibodies (56.7±16.3 vs. 56.3±14.4 years). Similarly, 
there were no substantial dif erences in the type and severity of 
neurological symptoms ( Figure 3 ). Finally, we also compared 
those patients with the HLA-DQ2 and -DQ8 vs. those without. 
We again did not i nd any dif erences between the two subgroups 
( Table 1 ).
AQ13
 Table 1 .  Summary of clinical and serological characteristics of the different groups 
  Group 1 
CD neurology 
 Group 2 
NCGS neurology 
 Group 2a NCGS neurology 
HLA - DQ2 or - DQ8 
 Group 2b NCGS neurology 
HLA - non-DQ2 or -DQ 8 
 CD classic gastro 
presentation 
 Number of patients  228 (41%)  334 (59%)  208/334  126/334  100 
 Age at onset of neurological 
symptoms 
 53 (13–90) years   57 (17–80) years  55 (19–85) years  N/A 
 Mean age at diagnosis 
of CD 
 52.6±15.3  N/A  N/A  N/A  43.8±15 
( P <0.0001 when 
compared with 
Group 1) 
 TG2 antibodies  91%  29%  34%  22%  97% 
 TG6 antibodies  67%  60%  63%  55%  38% 
 AGA antibodies  100% (by defi nition) 
 IgG 78% 
 IgA 65% 
 both 43% 
 100% (by defi nition) 
 IgG 68% 
 IgA 53% 
 both 21% 
 100% (by defi nition) 
 IgG 66% 
 IgA 57% 
 both 23% 
 100% (by defi nition) 
 IgG 71% 
 IgA 47% 
 both 18% 
 82% 
 IgG 88% 
 IgA 75% 
 both 63% 
 HLA type  DQ2 94% 
 DQ8 4% 
 DQ2 44% 
 DQ8 18% 
 DQ2 71% 
 DQ8 29% 
 DQ1 95%  DQ2 96% 
 DQ8 4% 
 AGA, anti-gliadin antibodies; CD, coeliac disease; Ig, immunoglobulin; N/A, not applicable; NCGS, non-coeliac gluten sensitivity; TG, transglutaminase. 
© 2016 by the American College of Gastroenterology The American Journal of GASTROENTEROLOGY
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immune system and this notion is also consistent with the AGA 
response seen in NCGS ( 19 ). Support for a role for the adaptive 
immune system also comes from another recent study showing 
that a signii cant number of patients with CD (29%) and NCGS 
(29%) develop other autoimmune disorders when compared with 
patients with irritable bowel syndrome (4%) ( 20 ).
 h e role of autoimmunity in CD is well established with a recog-
nized target autoantigen in the form of TG2. h e same is true for 
DH where the target antigen is TG3, an epidermal TG ( 9 ). We have 
previously shown that patients with gluten ataxia appear to have 
an immunological response against a primarily brain expressed 
TG, TG6 ( 12 ). All three TGs are capable of deamidating disease-
relevant gliadin peptides and form thioester complexes with gliadin 
peptides, and therefore form entities that drive T- and B-cell 
responses, respectively ( 21 ). h e prevalence of TG6 autoantibodies 
in the two groups was comparable (67% and 60%, respectively, in 
Groups 1 and 2). h is is in contrast to what was observed with 
TG2 antibodies that were more prevalent in the group with CD 
compared with NCGS (91% and 29%, respectively). h is observa-
tion suggests that the immunological trigger in neurology patients 
is distinct. Unlike CD that is characterized by TG2 overexpression 
and activity in the intestinal mucosa, which drives the immuno-
logical response, such abundance and overwhelming activity is 
unlikely the case for TG6, or TG3 in DH, and hence the response 
is much more subdued (at least as rel ected by the level of serum 
antibodies), perhaps also explaining the absence of the full-blown 
symptoms of enteropathy. It remains to be seen if an enhanced 
expression and activation of TG6 akin to the TG2 response in gut 
occurs at the site involved, i.e., within the cerebrospinal l uid in 
cases of gluten ataxia.
 h e presence of TG6 antibodies in a group of patients without 
the HLA-DQ2 or -DQ8 also suggests that production of such 
antibodies is not always strictly linked to the HLAs conferring 
risk for CD. Moreover, of interest is the fact that in the group of 
patients with neurological manifestations and no enteropathy who 
had either HLA-DQ2 or -DQ8, there was signii cant over-repre-
sentation of DQ8 (29%) when compared with Group 1 (4%). h is 
indicates that dif erences exist in the HLA proi le that predisposes 
to TG6 as opposed to TG2-driven autoimmunity. It remains to be 
seen if DQ8 and possibly DQ1 prove to be important susceptibility 
HLAs for the NCGS neurology cohort.
 To investigate any inl uence of the HLA type and the presence 
or absence of TG2 antibodies within the NCGS group (Group 
2), we also analysed the data by dividing Group 2 into those with 
and without HLA-DQ2 or -DQ8 (see  Table 1 ) and those with and 
without positive TG2 antibodies ( Figure 3 ). Neither of these two 
parameters substantially inl uenced the type and severity of the 
neurological manifestations.
 h e presence of TG6 antibodies in 38% of patients with newly 
diagnosed CD presenting with the classic gastrointestinal symp-
toms to a gastroenterologist may suggest that these patients are sus-
ceptible to future development of neurological dysfunction if they 
continue to consume gluten. h is is also supported by the fact that 
patients with CD presenting with neurological problems are likely 
to be diagnosed with CD signii cantly later (mean age 52.6±15.3 
 DISCUSSION
 h is retrospective review of probably the largest cohort of patients 
presenting with neurological manifestations of GRD suggests that 
there are no clear distinguishing neurological features between 
those patients with CD and those with NCGS. Furthermore, the 
spectrum, severity, and response to GFD of these neurological 
manifestations were very similar between the two groups with 
some minor exceptions: gluten encephalopathy was more com-
monly associated with enteropathy, whereas neuropathy and 
ganglionopathy were less commonly associated with enteropathy. 
In terms of severity, patients in Group 1 tended to have a more 
severe neuropathy than those in Group 2. Irrespective of these 
dif erences, the neurological manifestations in both groups were 
equally responsive to a GFD. We have also previously shown that a 
subgroup of patients with gluten ataxia and myoclonus were more 
likely to belong to Group 1 (i.e., had enteropathy) and ot en had 
refractory CD ( 16 ). We have previously reported the benei cial 
ef ect of GFD in patients with gluten ataxia and gluten neuro pathy 
( 6,13 ). In those studies ,we again showed that the benei t of the 
diet was independent of the presence of enteropathy.
 NCGS belongs to the spectrum of GRD, but the pathogenesis, 
unlike CD, remains unclear. Involvement of innate immunity has 
been proposed ( 17 ). It is as yet unclear if the antigenic stimulus 
relates to gluten peptides or another component of wheat, e.g., 
amylase trypsin inhibitors ( 18 ).
 However, the mucosal cytokine proi le at er short-term gluten 
challenge observed in a recent study also implicates the adaptive 
Severity of ataxia
100%
Severity of neuropathy
Severe
Moderate
Mild
Severe
Moderate
Mild
80%
60%
70%
90%
40%
50%
20%
30%
10%
0%
Group 1 Group 2
100%
%
80%
60%
40%
20%
0%
Group 1 Group 2
 Figure 2 .  Severity of ataxia and neuropathy in the two groups: Group 1 
coeliac disease (CD) and Group 2 non-coeliac gluten sensitivity (NCGS). 
Moderate and severe neuropathy is more prevalent in Group 1 ( P =0.016 
by  χ 2 test), but there is no difference in the severity of ataxia in any group.
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years) when compared with those presenting with gastrointestinal 
symptoms (mean age 43.8±15 years). It could be argued that the 
presence of gastrointestinal symptoms of ers a therapeutic advan-
tage to these patients as it increases the likelihood of them being 
diagnosed and treated early, as opposed to the neurology patients 
who on average are diagnosed 10 years later.
 As yet, it is unknown at what stage of the immunological response 
against gluten that TG autoantibodies (TG2, TG3, and TG6) are i rst 
produced and appear systemically in relation to the development 
of symptoms. Although inferable from various lines of evidence, it 
has not been directly demonstrated that the patients with neuro-
logical manifestations (particularly those with CNS involvement) 
have such antibodies in their cerebrospinal l uid, and whether these 
antibodies are produced locally or derived from the circulation. 
However, immunoglobulin deposits against TG6 can be found in 
the cerebellum of patients with GA and deposits against TG2 can be 
found in the brain vessel wall in patients with GA ( 12,22 ).
 Further evidence in support of a role for TG antibodies in disease 
pathogenesis comes from mouse models. TG antibodies (TG2 and 
TG6) cause ataxia-like dei cits following intraventricular injection 
( 23 ). Antibodies forming the characteristic deposits in the papil-
lary dermis in DH are derived from the circulation, indicating that 
extraintestinal manifestations of GRD are antibody mediated ( 24 ). 
Furthermore, HLA-DQ8 transgenic mice develop some features of 
gluten sensitivity analogous to NCGS that are gluten dependent.
 An important i nding in this study is that patients with NCGS can 
present with neurological dysfunction in an identical manner to those 
patients with CD, suggesting similar immunological processes being 
responsible at least for the neural damage. h is is also supported 
by the similar prevalence of TG6 antibodies in the two groups.
 All the neurology patients described in this report were selected 
on the basis of positive antigliadin antibodies. Unfortunately, this 
serological test is no longer in general use as immunology labora-
tories are preferentially using newer assays (e.g., deamidated glia-
din, endomysium, and TG2 antibody assays). h ese newer assays 
are far superior for diagnosing CD as they are based on specii c 
molecular events occurring in CD pathogenesis, but unfortunately 
such assays are of limited use in the diagnosis of patients without 
enteropathy (Group 2) where molecular preferences show a bias that 
is distinct. Hence, in cases without enteropathy, the less selective 
marker AGA can provide an indication that further investigation 
is warranted, although not diagnostic by itself. In our experience, 
patients with NCGS are equally likely to respond to a strict GFD 
as are those patients with CD and neurological manifestations. 
Although TG6 antibody testing appears to be more specii c for the 
neurological manifestations even in the absence of enteropathy, it 
is not as yet readily available. Currently, the best approach would 
be to include all serological testing (TG2, TG6, anti-endomysium 
antibodies, AGA) for patients suspected of having GRD.
 Increasing recognition of the whole spectrum of GRD is the 
only way of improving diagnosis and thus avoiding the common 
problem of patients with neurological manifestations remaining 
untreated if duodenal biopsy does not reveal an enteropathy.
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 Study Highlights
 WHAT IS CURRENT KNOWLEDGE 
 ✓  NCGS refers to patients with sensitivity to gluten in the 
absence of an enteropathy. 
 ✓  There is no reliable serological marker for this entity. 
 ✓  Not much is known of any neurological manifestations and 
any differences from patients with CD. 
 ✓  The pathophysiology remains elusive. 
 WHAT IS NEW HERE 
 ✓  Patients with NCGS develop neurological manifestations. 
 ✓  Such neurological manifestations are similar to what is 
seen in patients with CD. 
 ✓  Such patients may benefi t from a GFD. 
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